Chunghwa Chemical Synthesis & Biotech Co Ltd

Chunghwa Chemical Synthesis & Biotech has a market price of TWD 38.75, with a market capitalization of TWD 2.98 billion. The company's price-to-book ratio is 0.97, and its price-to-tangible-book ratio is also 0.97, indicating that the market value is slightly below the book value of tangible assets. The enterprise value to EBITDA is negative at -11.85, reflecting the company's current unprofitability. The enterprise value to revenue is 4.7, suggesting a relatively high valuation relative to its revenue. The company's profitability is weak, with a return on equity of -7.9% and a return on assets of -5.65%. These figures are significantly below the industry median for pharmaceutical companies, which typically exhibit positive returns on equity and assets. The company's operating income and net income are both negative, at TWD -319.4 million and TWD -243.8 million, respectively, indicating a challenging operating environment. Chunghwa Chemical Synthesis & Biotech's revenue is concentrated in the domestic market and overseas markets, including the rest of Asia, the Americas, and Europe. However, the company does not disclose specific revenue by segment or geography, making it difficult to assess the concentration risk in detail. The lack of detailed segment reporting limits the ability to evaluate the performance of individual product lines or geographic regions. The company's growth trajectory is uncertain, with no clear indication of revenue growth in the current fiscal year. Analysts have issued a single "Hold" recommendation, with no "Buy" or "Strong Buy" ratings, suggesting a cautious outlook. The company's free cash flow is negative at TWD -129.6 million, and its capital expenditure is TWD -62.3 million, indicating that the company is not generating sufficient cash to fund its operations and investments. The company faces several risk factors, including liquidity risk due to negative net cash after subtracting total debt. The debt-to-equity ratio is 0.26, which is relatively low, but the company's operating cash flow is only TWD 142.6 million, which is insufficient to cover its debt obligations. The risk assessment indicates a medium level of liquidity risk and a low level of dilution risk. Recent events, including the company's financial performance and analyst recommendations, suggest a challenging operating environment. The company's last actual EPS was -TWD 4.39, significantly below the mean EPS estimate of TWD 0.45, indicating a wide gap between expectations and actual performance. The company's financial statements and disclosures do not provide additional insights into recent strategic initiatives or operational changes.